Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.
Study Type
OBSERVATIONAL
Enrollment
10
Federal University of Rio de Janeiro
Rio de Janeiro, Rio de Janeiro, Brazil
Steatosis, without fibrosis or inflammation
Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
Time frame: 12 months
Steatohepatitis, with fibrosis
Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.